Reimbursement
Reimbursement for Ultrasound Renal Denervation
Improving Patient Access
Reimbursement resources for Transitional Pass-through (TPT) payment
Effective January 1, 2025, the Centers for Medicare & Medicaid Services (CMS) approved a Transitional Pass-through (TPT) payment for Paradise® Ultrasound Renal Denervation (uRDN) for outpatient procedures. TPT provides incremental payment in addition to the applicable Ambulatory Payment Classifications (APC) payment to recognize the additional cost of Paradise uRDN. CMS also issued a distinct device category for Paradise uRDN, recognizing the highly differentiated novel and effective treatment in patients with uncontrolled hypertension.
Refer your Medicare patients struggling with uncontrolled hypertension today!
Paradise uRDN TPT Payment Overview
- The additional TPT payment for Paradise uRDN became effective January 1, 2025, and is expected to remain effective for up to three years.
- TPT provides incremental payment for outpatient and ASC procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries.
- The distinct HCPCS code – C1736 Ultrasound Renal Denervation – highlights the differentiated treatment of uRDN.
For Medicare Fee-For-Service (FFS) patients
- Transitional Pass-Through (TPT) payment by Centers for Medicare and Medicaid Services (CMS) provides an incremental payment for new technologies in the hospital outpatient setting
- Through TPT, Paradise uRDN now has full device reimbursement available for Medicare Fee-for-Service (FFS) patients only. (Does not apply to Medicare Advantage or commercial insurance patients)
- Both Hospital outpatient facilities and Ambulatory Surgery Centers (ASCs) are eligible for TPT payment
For Non Medicare Fee-For-Service (FFS) patients
Reimbursement may vary for these patients based on the following elements:
Insurance Type
Private Payer & Medicare Advantage
Patient Diagnosis
Resistant HTN
Prior Auth. Requirements
Prior Auth. Highly Recommended
Reimbursement 2026
Based on Private Contracts
The new HCPCS C-Code for the Paradise uRDN System must be reported on the hospital outpatient claim; C1736: Catheter, Renel Denervation, Ultrasound
Our reimbursement team is available to help educate your institution on TPT payments. Contact us at reimbursement@recormedical.com
| 2026 | CPT Procedure Code | Device Code (C-Code) | C-Code Description | APC Mapping | Total Payment | Potential Medicare National Payment Rate |
| 0339T (Bilateral) | C1736 | Catheter Renal Denervation, Ultrasound | 5192 | APT + TPT Payment | $28,815 |
1. 0338T (Renal Denervation, Unilateral) has the same device offset % as 0339T with the same potential payment
TPT and Reimbursement Resources
Paradise Ultrasound RDN Reimbursement Support
To facilitate patient access, our dedicated team can assist you with education on, and submission of, prior authorizations and appeals for the Paradise uRDN procedure. If you are a healthcare provider and would like additional information or assistance, reach out to our reimbursement team.
The information contained in this resource is provided for general educational and informational purposes only and is not intended to constitute legal, financial, or clinical advice. Recor Medical, Inc. does not guarantee reimbursement or payment, nor is this material intended to increase or maximize payment by any payer. Nothing in this document should be viewed as instructions for selecting any particular code, and Recor Medical does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding accuracy, billing, and obtaining reimbursement rests with the healthcare provider or facility. Information provided is gathered from third-party sources and is subject to change without notice due to frequently changing laws, rules and regulations. It is important to consult with appropriate professionals, such as your Medicare contractor, the patient’s plan, legal counsel, reimbursement specialists, or coding experts, for specific guidance and interpretation of coding, coverage, and payment policies. This information is for FDA approved indications only. Where reimbursement is requested for a use not expressly specified in Recor Medical FDA approved labeling (including but not limited to instructions for use, operator’s manual or package insert) consult with your billing advisors or payers for advice on handling such billing issues. Use of this document is completely voluntary by the healthcare provider and is not intended to be a substitute for, or to influence, the independent medical judgment of the physician.